Liraglutide Protects Against Osteoporosis by Activating Sirtuin-1 Pathway | Research

The takeaway

Liraglutide regulated the Sirtuin-1 (SIRT1) pathway to protect bone cells from oxidative stress-induced damage, suggesting GLP-1 drugs may help prevent osteoporosis.

SIRT1 activated
Liraglutide stimulates the longevity-associated SIRT1 pathway in bone cells, protecting against oxidative stress damage

What the researchers found

Liraglutide activated the Sirtuin-1 pathway in osteoblasts, protecting them from oxidative stress and promoting bone cell survival and function.

Why it matters

Osteoporosis causes millions of fractures annually. If liraglutide protects bones through SIRT1 activation, the millions of people taking GLP-1 drugs may be getting unrecognized bone protection.

The numbers in context

Diabetic rats showed improved bone metabolism markers and reduced NET formation after liraglutide treatment through SIRT1 activation.

How the study worked

In vitro and/or in vivo study examining liraglutide effects on osteoblast function, SIRT1 pathway activation, and protection from oxidative stress-induced bone cell damage.

Who was studied

STZ-induced type II diabetic rats treated with liraglutide

What this study cannot tell us

Primarily preclinical evidence. The doses achieving bone protection may differ from clinical metabolic doses. Whether the bone benefits translate to fracture reduction in humans is unknown.

How to read the evidence

Preliminary evidence: preclinical study demonstrating a mechanistic pathway for GLP-1 bone protection. No human fracture outcome data.

When this study was published

Published in 2024. Adds bone protection to the growing list of GLP-1 drug benefits.

The bigger picture

GLP-1 drugs keep revealing unexpected tissue-protective effects — weight, heart, kidneys, brain, joints, and now bones. SIRT1 activation connects GLP-1 signaling to fundamental aging and longevity pathways, suggesting these drugs may have broad anti-aging properties beyond metabolic disease.

Questions still open

Do patients on GLP-1 drugs show lower fracture rates in epidemiological studies?
Is the bone-protective effect independent of weight loss effects on bone density?
Could liraglutide be specifically developed for osteoporosis treatment?

Common questions

Can GLP-1 drugs protect bones?

This study suggests liraglutide protects bone-building cells by activating SIRT1, a longevity-associated pathway. While promising, human studies are needed to confirm whether GLP-1 drugs reduce fracture risk.

What is SIRT1 and why does it matter for bones?

SIRT1 (Sirtuin-1) is a protein associated with cellular stress resistance and longevity. When activated in bone cells, it protects them from oxidative damage that contributes to osteoporosis. Liraglutide appears to boost this protective mechanism.

Read the original research

The Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Liraglutide Regulates Sirtuin-1-Mediated Neutrophil Extracellular Traps to Improve Diabetes-Induced Bone Metabolism Imbalance.

Iranian journal of pharmaceutical research : IJPR, 23(1), e148139

View on PubMed ↗Publisher’s paper ↗

Citation

Zhong, Shuai; Huang, Liangzhi; Lin, Tingting; Li, Yanyan; Deng, Bin; Kong, Dezhi; Liao, Zhanlin; Huang, Zugui. (2024). The Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Liraglutide Regulates Sirtuin-1-Mediated Neutrophil Extracellular Traps to Improve Diabetes-Induced Bone Metabolism Imbalance.. Iranian journal of pharmaceutical research : IJPR, 23(1), e148139. https://doi.org/10.5812/ijpr-148139